Three major drugmakers recently announced refunds for 340B covered entities that purchased certain drugs in 2022 and 2023 following recalculations [...] …
Category: Pharma Industry
In the final hour of Oklahoma’s 2025 legislative session, as the clock neared 11 p.m. on May 29, state legislators [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
For the third straight time in 2025, a federal audit has found a drug manufacturer overcharged covered entities for 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A recent drug-industry-funded study attributes the 340B program’s recent growth to increased utilization—not rising drug prices. The May 21 study, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Novartis and Bristol Myers Squibb (BMS) are asking a federal appeals court to expedite their challenge to a recent ruling [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical giant Amgen recently announced it will exempt Tennessee providers from its contract pharmacy restrictions despite a carve out in [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SpecGx, a generic subsidiary of Mallinckrodt Pharmaceuticals, will refund 340B covered entities that purchased addiction treatment medication Methadose for above [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Oregon Legislature yesterday sent a 340B contract pharmacy access bill to the state’s governor, shortly after Illinois lawmakers failed [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical giant AbbVie has sued Hawaii over its 340B contract pharmacy access law just three days after the governor signed [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Department of Health and Human Services (HHS) has submitted proposed 340B rebate guidance for regulatory review—but it is unclear [...] …